Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma.

Chia-Ching Wang,Cassandra Thanh,Erica A Gibson,Maya Ball-Burack,Louise E Hogan, Benjamin Descours,Norman Jones,Alexander B Carvidi,Sadie Munter,Sonia Bakkour,Michael P Busch,Jeffrey M Milush,Steven G Deeks,Timothy J Henrich

Blood advances（2018）

引用 13|浏览36

暂无评分

摘要

Key Points Anti-CD30 therapy for Hodgkin lymphoma led to transient loss of detectable CD4 + T-cell HIV RNA and a decrease in residual plasma viremia. Targeting nonviral markers expressed on HIV-1 transcriptionally active cells may lead to reduced measures of HIV-1 persistence.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要